France - français - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

becton dickinson france sa - gluconate de chlorhexidine 60 mg; alcool isopropylique 2 - solution - 60 mg - pour 3 ml de solution pour application cutanée > gluconate de chlorhexidine 60 mg > alcool isopropylique 2,1 ml - chlorhexidine en association - classe pharmacothérapeutique - chlorhexidine en association - code atc : d08ac52le chloraprep colore, solution pour application cutanée est une solution antiseptique pour application cutanée.le chloraprep colore, solution pour application cutanée est une solution cutanée de gluconate de chlorhexidine à 2 % m/v et d'alcool isopropylique à 70 % v/v contenue dans un applicateur en plastique doté d'une éponge en son extrémité. l'applicateur contient une solution antiseptique à action rapide, utilisée pour désinfecter la peau et prévenir des infections avant une intervention médicale invasive comme une injection, l'insertion de cathéters et une intervention chirurgicale mineure ou majeure. le chloraprep colore, solution pour application cutanée contient un colorant permettant de colorer la peau, mais qui n’a pas de rôle dans les propriétés antiseptiques de la solution.

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

gebro pharma ag - iodum, l'alcool isopropylicus - teinture colorée - l'iode 1 mg à povidonum iodinatum, l'alcool isopropylicus 550 mg, color.: e 110, excipiens ad solution de 1 ml. - hautdesinfiziens - synthetika

Union européenne - français - EMA (European Medicines Agency)

les laboratoires servier - trifluridine, tipiracil de chlorhydrate de - néoplasmes colorectaux - agents antinéoplasiques - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

France - français - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

laboratoires gilbert - chlorhexidine (gluconate de) - solution - 0,5 g - composition pour 100 ml > chlorhexidine (gluconate de) : 0,5 g . sous forme de : solution de digluconate de chlorhexidine 2,66 g > éthanol à 96 pour cent : 75 ml - antiseptiques et desinfectants

France - français - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

gifrer barbezat - chlorhexidine (gluconate de) 0 - solution - 0,50 g - pour 100 ml de solution > chlorhexidine (gluconate de 0,50 g sous forme de : solution de digluconate de chlorhexidine - antiseptiques et desinfectants - classe pharmacothérapeutique : antiseptiques et desinfectants, code atc : d08ac02.il est utilisé pour l'antisepsie de la peau saine avant et après acte de petite chirurgie.

France - français - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

gifrer barbezat - digluconate de chlorhexidine - solution - 50 mg - composition pour 100 ml de solution > digluconate de chlorhexidine : 50 mg . sous forme de : solution de digluconate de chlorhexidine - - antiseptiques et desinfectants (d dermatologie) –

France - français - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

laboratoires gilbert - gluconate de chlorhexidine 0 - solution - 0,0500 g - pour 100ml de solution pour application locale > gluconate de chlorhexidine 0,0500 g sous forme de : solution de digluconate de chlorhexidine 0,2500 g - · antiseptique bactéricide à large spectre. - classe pharmacothérapeutique - code atc : d08ac02ce médicament est un antiseptique (il lutte contre la prolifération des microbes)indications thérapeutiquesce médicament est préconisé dans l’antisepsie des plaies superficielles et peu étendues.

Union européenne - français - EMA (European Medicines Agency)

merck europe b.v.  - cetuximab - head and neck neoplasms; colorectal neoplasms - agents antinéoplasiques - erbitux est indiqué pour le traitement des patients atteints de facteur de croissance épidermique (egfr) exprimant, ras de type sauvage d'un cancer colorectal métastatique:en combinaison avec des chimiothérapies à base d'irinotécan, dans la première ligne en association avec le folfox;en monothérapie chez des patients qui n'ont pas d'oxaliplatine et d'irinotécan thérapie et qui sont intolérants à l'irinotécan. pour plus de détails, voir la section 5. erbitux est indiqué pour le traitement de patients avec le cancer des cellules squameuses de la tête et du cou:en combinaison avec la radiothérapie pour les cancers localement avancés de la maladie;en combinaison avec la chimiothérapie à base de platine pour récidivant et/ou métastatique de la maladie.

Union européenne - français - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; mesothelioma; colorectal neoplasms - agents antinéoplasiques - melanomaopdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older. relative to nivolumab monotherapy, an increase in progression free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression. adjuvant treatment of melanomaopdivo as monotherapy is indicated for the adjuvant treatment of adults and adolescents 12 years of age and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. non-small cell lung cancer (nsclc)opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. opdivo as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. malignant pleural mesothelioma (mpm)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. renal cell carcinoma (rcc)opdivo as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor risk advanced renal cell carcinoma. opdivo in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. classical hodgkin lymphoma (chl)opdivo as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant (asct) and treatment with brentuximab vedotin. squamous cell cancer of the head and neck (scchn)opdivo as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy. urothelial carcinomaopdivo as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum containing therapy. adjuvant treatment of urothelial carcinomaopdivo as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (miuc) with tumour cell pd-l1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of miuc. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)opdivo in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy. oesophageal squamous cell carcinoma (oscc)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. adjuvant treatment of oesophageal or gastro-oesophageal junction cancer (oc or gejc)opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. gastric, gastro‑oesophageal junction (gej) or oesophageal adenocarcinomaopdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first‑line treatment of adult patients with her2‑negative advanced or metastatic gastric, gastro‑oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) ≥ 5.

Union européenne - français - EMA (European Medicines Agency)

amgen europe b.v. - le panitumumab - néoplasmes colorectaux - agents antinéoplasiques - vectibix is indicated for the treatment of adult patients with wild-type ras metastatic colorectal cancer (mcrc): , in first-line in combination with folfox or folfiri. en deuxième ligne, en association avec folfiri pour les patients qui ont reçu de première ligne à base de fluoropyrimidine chimiothérapie à base (à l'exclusion de l'irinotécan). en monothérapie après échec de la base de fluoropyrimidine-, d'oxaliplatine et d'irinotécan contenant des chimiothérapies.